Free newsletter
The Peptide Research Digest
Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.
Prices, providers, and published evidence — tracked independently, never an affiliate code. Get research updates as the data grows.
Free · occasional research updates only · unsubscribe in one click
Already a member? Sign in
Peptide Profile
Pegylated Mechano Growth Factor · PEGylated MGF
PEG-MGF (pegylated mechano growth factor) is a synthetic derivative of mechano growth factor (MGF, IGF-1Ec), in which the bioactive C-terminal E-peptide domain of the IGF-1 gene splice variant is chemically conjugated with…
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
Pegylated form of MGF; activates muscle stem cells (satellite cells) to repair and regenerate muscle tissue after damage
PEG-MGF (pegylated mechano growth factor) is a synthetic derivative of mechano growth factor (MGF, IGF-1Ec), in which the bioactive C-terminal E-peptide domain of the IGF-1 gene splice variant is chemically conjugated with polyethylene glycol (PEG) to improve aqueous stability and extend its proposed in vivo half-life relative to the rapidly degraded unmodified peptide. PEGylation is intended to preserve the proposed satellite cell-activating and tissue repair-promoting actions of the native MGF E-peptide over a longer post-administration window, with the pharmacological rationale extrapolated from preclinical and in vitro research on the parent MGF compound. No indexed peer-reviewed literature has been identified for PEG-MGF as a distinct chemical entity under its common name or under pegylated IGF-1 splice variant terminology in the biomedical literature, and the compound does not appear in PubMed with characterized pharmacokinetic or pharmacodynamic properties. PEG-MGF has no regulatory approval in any jurisdiction and no published human pharmacokinetic, safety, or efficacy data; it is sold as a research chemical by vendors without an evidence base establishing its biological activity as a defined and characterized therapeutic agent.
Commonly researched in the context of
Population research notes
These signals reflect research interest areas, not treatment indications.
PEGylated IGF-1 splice variant with extended half-life. No FDA approval. WADA prohibited. Not on any FDA list. Sold as research chemical. No NDA or IND.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research-use compound with limited human data. Evidence strength varies — see the Evidence section.
Absolute contraindications
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSPEG-MGF
Self-reported, anecdotal experiences aggregated from public Reddit discussions — community sentiment, not clinical evidence or medical advice.
Attribution note: many of these reports describe stacking PEG-MGF with other compounds, so outcomes may not be attributable to it alone.
Outcome distribution
Side effects people mention
Counts are mentions across reports, not incidence rates.
Most reported
What they wish they'd known
Based on 13 community reports · Updated
PEG-MGF (pegylated mechano growth factor) is a synthetic derivative of mechano growth factor (MGF, IGF-1Ec), in which the bioactive C-terminal E-peptide domain of the IGF-1 gene splice variant is chemically conjugated with polyethylene glycol (PEG) to improve aqueous stability and extend its proposed in vivo half-life relative to the rapidly degraded unmodified peptide. PEGylation is intended to preserve the proposed satellite cell-activating and tissue repair-promoting actions of the native MGF E-peptide over a longer post-administration window, with the pharmacological rationale extrapolated from preclinical and in vitro research on the parent MGF compound.
muscle repair, satellite cell activation, post-injury recovery.
Research on PEG-MGF primarily documents effects related to muscle repair and satellite cell activation and post-injury recovery. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
For PEG-MGF, its FDA status is Nomination Withdrawn, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
9 providers in the directory currently offer PEG-MGF.
Across 6 research vendors tracked on PeptideBase, PEG-MGF has a median price of about $23.50 per mg, typically ranging $16.17–$30.31 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.
PEG-MGF is featured in the following research stacks on PeptideBase: TB-500 + PEG-MGF: Muscle Repair & Regeneration.
Price per mg varies by quantity, vendor type, and formulation. Research use only.
Data verified July 2026 · PEG-MGF price intelligence
Commonly stacked with
Stay updated on verified PEG-MGF providers
New verified providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). PEG-MGF — Per-mg Price Benchmark. Retrieved July 22, 2026, from https://peptidebase.io/peptides/peg-mgf